NBY - NovaBay Pharmaceuticals, Inc.
| Previous Close | 0.9800 |
| Open | 0.9997 |
| Bid | 0.7000 x 900 |
| Ask | 1.3000 x 2200 |
| Day's Range | 0.9997 - 1.1000 |
| 52 Week Range | 0.7100 - 3.7500 |
| Volume | 7,815 |
| Avg. Volume | 31,677 |
| Market Cap | 18.963M |
| Beta (3Y Monthly) | 3.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4610 |
| Earnings Date | Mar 19, 2019 - Mar 22, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- Business Wire•3 days ago
NovaBay Pharmaceuticals Announces Annual Meeting of Stockholders and Receives NYSE American Communication
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will hold a virtual Annual Meeting of Stockholders on Thursday, May 30, 2019 at 5:00 p.m. Pacific time. Registered holders and beneficial stockholders, who register for the meeting in advance, will be able to participate in the meeting, vote and submit questions during the meeting via a live webcast by visiting www.meetingcenter.io/263757134. The Company also notes that on April 12, 2019 it received notice (the “Notice”) from the NYSE American LLC that it is not in compliance with Section 1003(a)(iii) of the NYSE American Company Guide requiring stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years.
- Business Wire•5 days ago
NovaBay Pharmaceuticals Announces New Partner Pharmacy Program
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company, announces a new pharmacy partnering program in a continued effort to ensure all patients in the U.S. have reliable and affordable access to prescription Avenova®. The company’s pharmacy partners serve patients across the U.S., and together ensure patients in all 50 states have convenient access to Avenova. “Our commitment to a quality patient experience, along with our expanding national presence ensures every patient who wants Avenova can obtain it at the best price,” said Dan Richards, CEO of Meds In Motion Pharmacy, one of Avenova’s channel partners.
- Business Wire•22 days ago
NovaBay Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results
Conference call begins today at 4:30 p.m. Eastern time
- ACCESSWIRE•23 days ago
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 28, 2019 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 28, ...
- Business Wire•last month
NovaBay Pharmaceuticals Announces Strategic Shift in U.S. Avenova Commercialization Strategy
Makes board and executive changes and reduces U.S. sales organization to focus only on high-performing, high potential sales territories and specialty pharmacy channel expansion
- Zacks•last month
Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for
NovaBay (NBY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•3 months ago
NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales and Introduces 2019 Net Sales Guidance
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces 2018 net sales are expected to be $12.6 million to $12.7 million. “During 2018 we launched a number of refinements to our Avenova commercial strategy as we gained experience from our initial approach,” said Jack McGovern, NovaBay Interim CEO and CFO. “Key drivers of our expected growth include engaging specialty pharmacy providers as channel partners, which provides the dual benefit of significantly improving the overall patient experience and supporting higher per-unit revenue,” he added.
- Business Wire•5 months ago
NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results
Conference call begins today at 4:30 p.m. Eastern time
- Business Wire•5 months ago
NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report third quarter 2018 financial results after market close on Wednesday, November 14.
- Zacks•5 months ago
Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know
NovaBay (NBY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•7 months ago
NovaBay Pharmaceuticals Names Jack McGovern Interim CEO
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that Jack McGovern has been named Interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the Company’s previous Chief Executive Officer, remains NovaBay’s Chairman and will focus on strategic growth opportunities that complement the Company’s continued organic growth.
- Business Wire•8 months ago
NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C.
- Business Wire•8 months ago
NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results
Conference call begins today at 4:30 p.m. Eastern time
- Business Wire•9 months ago
NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report second quarter 2018 financial results after market close on Tuesday, August 7.
- Business Wire•9 months ago
NovaBay Pharmaceuticals Expands Sales Organization to Re-energize Growth
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces it has completed the most recent planned expansion of its salesforce by hiring of 7 sales representatives. The Company now has a commercial salesforce of 45 representatives as the Company pursues profitable growth. “We are very encouraged by the high quality of our new hires, all of whom have significant experience in promoting prescription ophthalmic products,” said Mark M. Sieczkarek, NovaBay’s Chairman, President and CEO.
- Business Wire•11 months ago
NovaBay Pharmaceuticals Reports First Quarter 2018 Financial Results
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three months ended March 31, 2018 and provides a business update.
- Business Wire•11 months ago
NovaBay Pharmaceuticals to Hold First Quarter 2018 Conference Call on May 10, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10.
